多抗原人巨细胞病毒mRNA疫苗可诱导强效的体液免疫和细胞免疫
针对尚无获批疫苗的人巨细胞病毒(CMV),研究将编码gB和五聚体复合物(PC)的修饰mRNA包裹于脂质纳米颗粒(LNP)中免疫小鼠和非人灵长类,可诱导强效持久的 neutralizing 抗体滴度;另开发表达pp65的mRNA疫苗与PC、gB联用可在小鼠中诱导稳健的多抗原T细胞应答,提示mRNA/LNP是可针对不同目标人群设计CMV疫苗的通用平台。
要点
- 编码gB和PC的mRNA/LNP疫苗在小鼠和非人灵长类中诱导强效持久的中和抗体滴度。
- 表达pp65的mRNA疫苗与PC和gB联用可在小鼠中诱导稳健的多抗原T细胞应答。
- mRNA/LNP是可用于不同目标人群CMV疫苗策略开发的通用平台。
核心结论
- mRNA/LNP是通用平台,可支持开发针对不同目标人群、可能预防CMV感染及后续疾病的疫苗接种策略。
研究设计与样本
- 研究为动物实验,免疫小鼠和非人灵长类(NHP),使用包裹编码CMV糖蛋白gB和五聚体复合物(PC)的修饰mRNA的脂质纳米颗粒(LNP)。
- 另开发表达免疫优势CMV T细胞抗原pp65的mRNA疫苗,并与PC和gB疫苗联用于小鼠。
主要发现
- 小鼠和非人灵长类经编码gB和PC的mRNA/LNP免疫后,产生强效且持久的中和抗体滴度。
- pp65疫苗与PC和gB疫苗联用可在小鼠中诱导稳健的多抗原T细胞应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A cytomegalovirus (CMV) vaccine that is effective at preventing congenital infection and reducing CMV disease in transplant patients remains a high priority as no approved vaccines exist. While the precise correlates of protection are unknown, neutralizing antibodies and antigen-specific T cells have been implicated in controlling infection. We demonstrate that the immunization of mice and nonhuman primates (NHPs) with lipid nanoparticles (LNP) encapsulating modified mRNA encoding CMV glycoproteins gB and pentameric complex (PC) elicit potent and durable neutralizing antibody titers. Since the protective correlates in pregnant women and transplant recipients may differ, we developed an additional mRNA vaccine expressing the immunodominant CMV T cell antigen pp65. Administration of pp65 vaccine with PC and gB elicited robust multi-antigenic T cell responses in mice. Our data demonstrate that mRNA/LNP is a versatile platform that enables the development of vaccination strategies that could prevent CMV infection and consequent disease in different target populations.
引用
- John S, Yuzhakov O, Woods A, et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018. PMID: 29456015. doi:10.1016/j.vaccine.2018.01.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。